Business · 23/09/2022Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for NURTEC ODT Patent Extension
Summary
The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for NURTEC ODT, a human drug product, in accordance with US patent extension laws, following a submission to the US Patent and Trademark Office (USPTO).
Original source language: Federal Register — Food and Drug AdministrationOpen original release →